Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
0.7353
+0.0031 (0.42%)
At close: Jul 15, 2025, 4:00 PM
0.7500
+0.0147 (2.00%)
After-hours: Jul 15, 2025, 5:39 PM EDT
Context Therapeutics Employees
Context Therapeutics had 12 employees as of December 31, 2024. The number of employees increased by 7 or 140.00% compared to the previous year.
Employees
12
Change (1Y)
7
Growth (1Y)
140.00%
Revenue / Employee
n/a
Profits / Employee
-$2,302,881
Market Cap
65.96M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12 | 7 | 140.00% |
| Dec 31, 2023 | 5 | -4 | -44.44% |
| Dec 31, 2022 | 9 | 8 | 800.00% |
| Dec 31, 2020 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CNTX News
- 5 weeks ago - Context Therapeutics: Undervalued Cancer Fighter - Seeking Alpha
- 6 weeks ago - Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting - GlobeNewsWire
- 6 weeks ago - Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Context Therapeutics Reports First Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 2 months ago - Context Therapeutics Announces Chief Medical Officer Transition - GlobeNewsWire
- 2 months ago - Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting - GlobeNewsWire
- 3 months ago - Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 - GlobeNewsWire